Amarantus Bioscience Holdings Inc., of San Francisco and Geneva, reported top-line data from a 140-subject LP-002 study, demonstrating that multiple individual biomarkers achieved statistically significant results to correctly identify patients with Alzheimer's disease from healthy control using the company's Lympro Test, a lymphocyte proliferation diagnostic.